Questions Concerning the Proximal Origin of SARS-CoV-2

Murat Seyran  
*Universal Scientific Education and Research Network (USERN)*

Damiano Pizzol  
*Italian Agency for Development Cooperation - Khartoum, Sudan*

Parise Adadi  
*University of Otago, Dunedin*

Tarek M. El-Aziz  
*University of Texas Health Science Center at San Antonio*

Sk. Sarif Hassan  
*Pingla Thana Mahavidyalaya*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.usf.edu/usf_fcrc_all

**Scholar Commons Citation**
Seyran, Murat; Pizzol, Damiano; Adadi, Parise; El-Aziz, Tarek M.; Hassan, Sk. Sarif; Soares, Antonio; Kandimalla, Ramesh; Lundstrom, Kenneth; Tambuwala, Murtaza; Aljabali, Alaa A. A.; Lal, Amos; Azad, Gajendra K.; Choudhury, Pabitra P.; Uversky, Vladimir N.; Sherchan, Samendra P.; Uhal, Bruce D.; Rezaei, Nima; and Brufsky, Adam M., "Questions Concerning the Proximal Origin of SARS-CoV-2" (2021). *All publications*. 109.  
https://digitalcommons.usf.edu/usf_fcrc_all/109

This Article is brought to you for free and open access by the USF Libraries Florida COVID-19 Research Collections at Digital Commons @ University of South Florida. It has been accepted for inclusion in All publications by an authorized administrator of Digital Commons @ University of South Florida. For more information, please contact digitalcommons@usf.edu.
Authors

This article is available at Digital Commons @ University of South Florida: https://digitalcommons.usf.edu/usf_fcrc_all/109
Questions concerning the proximal origin of SARS-CoV-2

1 | SUMMARY

There is a consensus that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated naturally from bat coronaviruses (CoVs), in particular RaTG13. However, the SARS-CoV-2 host tropism/adaptation pattern has significant discrepancies compared with other CoVs, raising questions concerning the proximal origin of SARS-CoV-2. The flat and nonsunken surface of the sialic acid-binding domain of SARS-CoV-2 spike protein (S protein) conflicts with the general adaptation and survival pattern observed for all other CoVs. Unlike RaTG13, SARS-CoV-2 recombination presumably occurred between the S1/S2 domains of S protein enabling host furin protease utilization. Although millions of recorded cases have been recorded globally, SARS-CoV-2 S protein does not have any apparent further recombination, placing it in conflict with the recombination models of other CoVs. Similarly, the S protein receptor-binding domain (RBD) of SARS-CoV-2 has not accumulated high-frequency nonsynonymous substitutions, differentiating SARS-CoV-2 from other CoVs that have positive selection/adaptation mutations in their RBDs.

2 | DISCUSSION

Andersen et al. documented the possible natural origin of SARS-CoV-2 from BatCoV RaTG13. SARS-CoV-2 is the seventh zoonotic CoV virus capable of infecting humans, but the first and only human coronavirus (HCoV) with pandemic potential. Bat or rodent CoVs demonstrate certain specific changes in the S protein RBD, as well as the S protein glycan-binding N-terminal domain (NTD), during host tropism/adaptation. SARS-CoV-2, unlike other CoVs, does not have those signature changes, suggesting that these RBD and NTD subdomains are of very recent origin. The "Canyon Hypothesis" explains the development of canyons, depression zones, or cavities on the surfaces of influenza virus, human rhinovirus, and Meningo viruses. In CoVs (except SARS-CoV-2), the S protein NTD domain has several predicted glycan-binding domains, with a common feature being the hidden localization of these glycan-binding domains to cavities to limit their access to antibodies and immune cells. This pattern of CoVs is thought to be an evolutionary measure to restrict the recognition of these active sites by host immune system. HCoVs can evade detection by host glycan-binding immune receptors. Comparative genomic analysis of six HCoVs with their corresponding native bat or rodent CoVs suggests compatibility with the "Canyon Hypothesis" resulting from various adaptive S protein NTD nonsynonymous mutations near or at the glycan-binding domain which are predicted to result in these NTD domains being hidden below the protein surface. The predicted flat, nonsunken pattern of the SARS-CoV-2 S protein NTD glycan-binding domains conflicts with this evolutionary host tropism/adaptation strategy.

A template-switching mechanism is presumably responsible for the high rate of RNA recombination in CoVs. In host cells, CoV RNAs show discontinuous RNA synthesis materialized by pauses of the RNA-dependent recombination and subsequent jumps to downstream template acceptor sequences. This process results in subgenomic minus-strand RNAs which serve as templates for subgenomic messenger RNAs. Due to the mechanistic similarity to recombination, this process might be at the origin of recombinant CoVs co-opting other CoV or even host-related sequences. Instances include the mouse hepatitis coronavirus S protein NTD sialic acid-binding domain, likely arising from recombination of viral RNA with human galectin RNA sequences.

The furin recognition motif present at the SARS-CoV2 S1/S2 junction has no analogy in other "lineage B" beta-coronaviruses, including neither pangolin-CoV nor RaTG13. This indicates that the S protein S1/S2 junction is not a hot spot for RNA recombination termination that depends on a pattern swapping templates (copy-choice). In addition, clinical isolates of SARS-CoV-2 S protein have not indicated any further recombination in this S1/S2 area, suggesting that the addition of a motif for S1/S2 site furin cleavage constituted a unique recombination occurrence. Finally, the CoV-unique insertion of four aminoacids creating a novel RRAR furin cleavage site introduces two arginine codons CGG–CGG, whose usage is extremely rare in CoVs, further supporting the hypothesis of a unique recombination occurrence. HCoVs have high-frequency "hot spots" for nonsynonymous amino acid replacements that can possibly create a positive selection for host
tropism/adaptation, resistance to neutralizing antibodies, or immune evasion. Interestingly, clinical SARS-CoV-2 isolates to date have only a single high-frequency nonsynonymous mutation, D614G, in their S protein.9 Based on currently known mutation rates and patterns in clinical isolates of SARS-CoV-2, the S protein does not appear to be a mutational “hot spot” for SARS-CoV-2, unlike other human CoVs.

SARS-CoV-2 is the seventh HCoV, but the first HCoV with pandemic potential. SARS-CoV disappeared without a pandemic, and MERS-CoV is mostly endemic to the Arabian Peninsula with some additional limited traveler infections resulting in outbreaks in South Korea.3,4 These unique features of SARS-CoV-2 raise several questions concerning the proximal origin of the virus that require further discussion.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
Murat Seyran conceived the study. Adam M. Brufsky, Vladimir N. Uversky, Amos Lal, and Kenneth Lundstrom provided critical review. Nima Rezaei, Damiano Pizzol, Amos Lal, Samendra P. Sherchan, Vladimir N. Uversky, Kenneth Lundstrom, Tarek M. A. El-Aziz edited the article, and Murat Seyran, Parise Adadi, and Tarek M. A. El-Aziz formatted the article. All authors of the consortium interpreted the results and approved the final version for submission.

KEYWORDS
coronavirus, fusion protein, genetic variability, mutation

Murat Seyran1,2
Damiano Pizzol3
Parise Adadi4
Tarek M. A. El-Aziz5,6
Sk. Sarif Hassan7
Antonio Soares8
Ramesh Kandimalla9,10
Kenneth Lundstrom10
Murtaza Tambuwala11
Alaa A. Aljabali12
Amos Lal13
Gajendra K. Azad14
Pabitra P. Choudhury15
Vladimir N. Uversky16
Samendra P. Sherchan17
Bruce D. Uhal18
Nima Rezaei19,20
Adam M. Brufsky21

1Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Doctoral Studies in Natural and Technical Sciences (SPL 44), University of Vienna, Vienna, Austria
2Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Vienna, Austria
3Italian Agency for Development Cooperation - Khartoum, Al Amarat, Sudan
4Department of Food Science, University of Otago, Dunedin, New Zealand
5Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
6Department of Zoology, Faculty of Science, Minia University, El-Minia, Egypt
7Department of Mathematics, Pingla Thana Mahavidyalaya, Maligram, West Bengal, India
8CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India
9Kakatiya Medical College/MGM-Hospital, DME/TSPSC, Hyderabad, Warangal, Telangana, India
10PanTherapeutics, Lutry, Switzerland
11School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland, UK
12Department of Pharmaceutical Sciences, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan
13Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
14Department of Zoology, Patna University, Patna, India
15Applied Statistics Unit Indian Statistical Institute, Kolkata, West Bengal, India
16Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
17Department of Environmental Health Sciences, Tulane University, New Orleans, Louisiana, USA
18Department of Physiology, Michigan State University, East Lansing, Michigan, USA
19Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
20Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
21Department of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Correspondence
Damiano Pizzol, Italian Agency for Development Cooperation - Khartoum, Sudan St 33, Al Amarat, Sudan.
Email: damianopizzol8@gmail.com
Adam M. Brufsky, MD, PhD, University of Pittsburgh School of Medicine, Division of Hematology-Oncology, 300 Halket St, Pittsburgh, PA 15213.
Email: brufskyam@upmc.edu

ORCID
Parise Adadi http://orcid.org/0000-0003-4724-9463
Tarek M. A. El-Aziz https://orcid.org/0000-0002-3441-9673
REFERENCES


